Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07225361 · ClinicalTrials.gov registry record · Phase 4
Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis
A Phase 4 study of Multiple Sclerosis and Multiple Sclerosis (MS) - Relapsing-remitting, sponsored by Northwestern University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT07225361 is a Phase 4 study of Multiple Sclerosis and Multiple Sclerosis (MS) - Relapsing-remitting that is actively recruiting participants, run by Northwestern University. The registered enrollment target is 40 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07225361, a Phase 4 study of Multiple Sclerosis and Multiple Sclerosis (MS) - Relapsing-remitting, is actively recruiting participants, sponsored by Northwestern University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
In this prospective, open-label, single-arm, single-institution trial, the investigators will accomplish the following two aims: 1. study the safety and tolerability of Ublituximab (Briumvi) twice annually in participants with early MS over a treatment observation period of \~12 months. 2. study the pre- and post-treatment change in plasma neurofilament light chain, tested at baseline pre-Ublituximab treatment, and q24 weeks for 96 weeks post Ublituximab treatment initiation.
Conditions Studied
Interventions
- DRUG Ublituximab
Study Locations (1)
Illinois
- Northwestern Memorial Hospital - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-11-28 |
| Est. Completion | 2029-08-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07225361
The ClinicalTrials.gov registry entry for NCT07225361 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (93% lower). The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which Ublituximab is the first listed.
NCT07225361 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT07225361 about?
NCT07225361 is a clinical study titled "Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis". In this prospective, open-label, single-arm, single-institution trial, the investigators will accomplish the following two aims: 1. study the safety and tolerability of Ublituximab (Briumvi) twice annually in participants with early MS over a treatment observation period of \~12 months. 2. study th...
What is the current status of trial NCT07225361?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2025-11-28. Estimated completion is 2029-08-01.
What conditions does trial NCT07225361 study?
This clinical trial studies the following conditions: Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting.
What interventions are being tested in trial NCT07225361?
The interventions under investigation include: Ublituximab (DRUG).
Who is sponsoring clinical trial NCT07225361?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07225361 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis
RECRUITING · Phase 4
-
Glucose Consumption in MS Using [F-18]FDG-PET
RECRUITING · Phase 4
-
Home Based Infusions for Ocrelizumab
RECRUITING · Phase 4
-
Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
RECRUITING · Phase 4
-
Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis
RECRUITING · Phase 4
-
Cladribine Tablets After Treatment With Natalizumab (CLADRINA)
ACTIVE NOT RECRUITING · Phase 4
Explore more on PlainTrial
Multiple Sclerosis
All registered trials for this condition
Multiple Sclerosis (MS) - Relapsing-remitting
All registered trials for this condition
Illinois
All trials with a study site in Illinois
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.